In April 2026, the Directorate General of Foreign Trade (DGFT) introduced a mandatory pre-shipment certification requirement for all active pharmaceutical ingredient (API) exports from India. The rule applies to IEC (Importer-Exporter Code) holders classified under HS chapters 29 and 30, and requires third-party laboratory validation before customs clearance.
Unlike earlier self-declaration models, this change centralises API quality verification and tightens traceability. For mid-sized manufacturers and trader-exporters, this means new process steps, documentation burdens and timelines—but also reduced dispute risk with overseas buyers and regulators.
Market signals
From April 2026, all API shipments require a DGFT-notified laboratory certificate confirming purity, identity and manufacturing compliance before customs release. Self-certification is no longer acceptable. The certificate must be linked to the IEC and shipment bill of entry.
DGFT has published a list of ~40 approved third-party testing labs across major pharma hubs (Gujarat, Maharashtra, Karnataka, Andhra Pradesh, Telangana). Testing turnaround is typically 5–7 working days, adding to pre-shipment timelines and working capital pressure for exporters.
The certificate is now tied to your IEC and tracked in DGFT's online system. Buyers receive verifiable proof of API quality; exporters build a regulatory portfolio that eases re-exports and audits by overseas pharma regulators (FDA, EMA, etc.).
Under India's Foreign Trade (Development & Regulation) Act, 1992, and the Foreign Trade Policy (FTP) 2023–28, the DGFT has the authority to prescribe pre-export certification. This April 2026 change is mandatory for all IEC holders exporting APIs (HS 2939, 2940, 3001–3006 category). Non-compliance risks IEC suspension, customs detention and buyer contract breaches. Vinayakam Consultants advises exporters to engage an approved lab immediately, map testing timelines into production and shipment schedules, and document chain-of-custody from manufacture to lab to customs. We help structure your testing protocol, liaise with labs, and ensure IEC records align with DGFT's digital linkage system to avoid clearance delays.
Your action checklist
- Identify an approved DGFT laboratory within your nearest pharma cluster; request their testing protocol, cost per batch and typical turnaround time, then factor into your production timeline.
- Audit your current API manufacturing records (batch logs, test reports, storage conditions) to confirm they meet the lab's input requirements—missing data will slow certification.
- Map a pilot shipment with your test lab and DGFT system before committing production to the new process; confirm IEC-certificate linkage is live and visible to customs brokers.
- Brief all overseas buyers on the new certificate; provide them a sample so they recognise its format, and confirm their regulatory body (FDA, EMA, etc.) accepts DGFT-notified lab certs as proof of API compliance.
Frequently asked questions
From April 2026, all API exports from India require mandatory pre-shipment certification from DGFT-notified third-party laboratories confirming purity, identity and manufacturing compliance before customs clearance. Self-certification is no longer acceptable.
IEC holders classified under HS chapters 29 and 30 exporting active pharmaceutical ingredients are affected. All API shipments now require third-party laboratory validation linked to the IEC and bill of entry.
Testing turnaround at approved third-party labs is typically 5–7 working days. DGFT has published ~40 approved labs across major pharma hubs in Gujarat, Maharashtra, Karnataka, Andhra Pradesh, and Telangana.